PHIO
Phio Pharmaceuticals Corp.
NASDAQ · Healthcare · Biotechnology · US
$1.03
+0.98%Sep 14, 2026, 11:00 UTC
Phio Pharmaceuticals Corp. announced a key development milestone for PH-762, submitting a filing to the FDA to support the next stage of clinical development in cutaneous squamous cell carcinoma.
Source:Jul 21, 2026, 00:00 UTC
Phio Pharmaceuticals Corp. appointed R. Todd Plott, M.D. as a member of its Board of Directors and the Governance Committee, effective July 20, 2026.
Jun 24, 2026, 11:00 UTC
Phio Pharmaceuticals commenced first commercial-scale cGMP production of its lead candidate PH-762 drug substance at Nitto Denko Avecia.
Source: